Beclobrate (BioDeep_00000176483)

   

human metabolite blood metabolite


代谢物信息卡片


2-(4-((4-Chlorophenyl)methyl)phenoxy)-2-methylbutanoic acid ethyl ester

化学式: C20H23ClO3 (346.13356380000005)
中文名称: 苄氯贝特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC(C)(C(=O)OCC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl
InChI: InChI=1S/C20H23ClO3/c1-4-20(3,19(22)23-5-2)24-18-12-8-16(9-13-18)14-15-6-10-17(21)11-7-15/h6-13H,4-5,14H2,1-3H3

描述信息

C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents
D009676 - Noxae > D000963 - Antimetabolites

同义名列表

5 个代谢物同义名

2-(4-((4-Chlorophenyl)methyl)phenoxy)-2-methylbutanoic acid ethyl ester; ethyl 2-{4-[(4-chlorophenyl)methyl]phenoxy}-2-methylbutanoate; Beclobrate, (+-)-isomer; Beclobric acid; Beclobrate



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • S Mayer, E Mutschler, L Z Benet, H Sphahn-Langguth. In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. Chirality. 1993; 5(3):120-5. doi: 10.1002/chir.530050304. [PMID: 8338721]
  • S Mayer, H Spahn-Langguth, I Gikalov, E Mutschler. Pharmacokinetics of beclobric acid enantiomers and their conjugates after single and multiple oral dosage of racemic beclobrate. Arzneimittel-Forschung. 1993 Jan; 43(1):40-3. doi: NULL. [PMID: 8447845]
  • S Mayer, E Mutschler, H Spahn-Langguth. Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). Chirality. 1991; 3(1):35-42. doi: 10.1002/chir.530030108. [PMID: 2039683]
  • C Wanner, H Wieland, P Schollmeyer, W H Hörl. Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia. European journal of clinical pharmacology. 1991; 40 Suppl 1(?):S85-9. doi: NULL. [PMID: 2044651]
  • C Manzoni, M R Lovati, A Bonelli, G Galli, C R Sirtori. Differential effects of beclobrate on lipid/lipoprotein distribution in normal and hypercholesterolemic rats. European journal of pharmacology. 1990 Nov; 190(1-2):39-49. doi: 10.1016/0014-2999(90)94110-j. [PMID: 2076759]
  • C Wanner, H Wieland, M Nauck, G Schaeffer, P Schollmeyer, W H Hörl. Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1990; 5(8):588-93. doi: 10.1093/ndt/5.8.588. [PMID: 23275992]
  • J Sznajd, B Idzior-Waluś, J Zabiński, I Wybrańska, G Korzus, J Iwanejko. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. I. Effect on cholesterol, lipid and apoprotein levels]. Przeglad lekarski. 1990; 47(10):706-10. doi: NULL. [PMID: 2089449]
  • J Sznajd, B Idzior-Waluś, G Korzus, J Zabiński, A Hebda, M Markiewicz. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. II. Results of the treatment in relation to the type of hyperlipoproteinemia]. Przeglad lekarski. 1990; 47(10):711-4. doi: NULL. [PMID: 2089450]
  • P Avogaro, G Bittolo Bon, G Cazzolato, S Soldan, L Bufalino. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia. Drugs under experimental and clinical research. 1989; 15(6-7):325-33. doi: NULL. [PMID: 2686956]
  • T A Kocarek, D R Feller. Induction of peroxisomal fatty acyl-CoA oxidase and microsomal laurate hydroxylase activities by beclobric acid and two metabolites in primary cultures of rat hepatocytes. Biochemical pharmacology. 1987 Sep; 36(18):3027-32. doi: 10.1016/0006-2952(87)90219-x. [PMID: 3632723]
  • I Gikalov, U Ifflaender. [Pharmacokinetics and bioequivalence of two peroral beclobrate preparations]. Arzneimittel-Forschung. 1987 Sep; 37(9):1065-8. doi: NULL. [PMID: 3435603]
  • K Anwer, J Gabis, K Romstedt, C Gojer, Huzoor-Akbar. Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis. Life sciences. 1985 Jul; 37(1):63-70. doi: 10.1016/0024-3205(85)90626-5. [PMID: 3925267]
  • V W Roth, A Prox, U Ifflaender. [Metabolism of beclobrate in rat and man]. Arzneimittel-Forschung. 1985; 35(1A):244-51. doi: NULL. [PMID: 4039165]
  • D Kritchevsky, S A Tepper, M A Mueller, D M Klurfeld. Influence of beclobrate and eniclobrate on cholesterol metabolism in rats. Arzneimittel-Forschung. 1983; 33(10):1469-71. doi: NULL. [PMID: 6686045]
  • D Kritchevsky, D M Klurfeld. Influence of beclobrate on gallstone formation in hamsters. Arzneimittel-Forschung. 1983; 33(10):1471-2. doi: ". [PMID: 6686046]
  • C Najemnik, H Lageder, H Regal, K Irsigler. Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b. Arzneimittel-Forschung. 1981; 31(12):2168-9. doi: ". [PMID: 7037012]